Natixis’s Contineum Therapeutics CTNM Stock Holding History

Natixis’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$144K	Buy	+9,072	New	+$119K	﹤0.01%	969

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Natixis's CTNM Position: Q2 2026 in Review

Natixis opened a new position in Contineum Therapeutics (CTNM) in Q2 2026: 9,072 shares worth $144K. The stake represents ﹤0.01% of the portfolio and ranks #969 among its holdings.

102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Natixis held 9,072 shares of Contineum Therapeutics worth $144K as of Q2 2026.
Contineum Therapeutics was a new Natixis position in Q2 2026.
Contineum Therapeutics made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #969 holding.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.